» Articles » PMID: 37646052

An Overview of Nanostructured Lipid Carriers and Its Application in Drug Delivery Through Different Routes

Overview
Journal Adv Pharm Bull
Date 2023 Aug 30
PMID 37646052
Authors
Affiliations
Soon will be listed here.
Abstract

Nanostructured Lipid Carriers (NLC) are nano-sized colloidal drug delivery system that contains a lipid mixture consisting of both solid and liquid lipids in their core. This Lipid-Based Nanosystem is introduced as a biocompatible, non-toxic, and safe nano-drug delivery system as compared to polymeric or metallic nanoparticles. Due to its safety, stability, and high drug loading capacity compared to other lipid-based nanocarriers, NLC gained the attention of researchers to formulate safe and effective drug carriers. The ability to increase drug solubility and permeability while encapsulating the drug in a lipidic shell makes them an ideal carrier for drug delivery through difficult-to-achieve routes. Surface modification of NLC and the use of various additives result in drug targeting and increased residence time. With such qualities, NLCs can be used to treat a variety of diseases such as cancer, infections, neurodegenerative diseases, hypertension, diabetes, and pain management. This review focuses on the recent developments being made to deliver the drugs and genes through different routes via these nanocarriers. Here, we also discuss about historical background, structure, types of NLC and commonly employed techniques for manufacturing lipid-based nanocarriers.

Citing Articles

Novel drug delivery systems in topical treatment of atopic dermatitis.

Dabhadkar M, Kulkarni M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40080153 DOI: 10.1007/s00210-025-04002-4.


Effects of beta and gamma radiation sterilization on growth factor-loaded nanoparticles: an innovative approach for osteoarticular disorders treatment.

Ordoyo-Pascual J, Ruiz-Alonso S, Gallego I, Saenz-Del-Burgo L, Pedraz J Drug Deliv Transl Res. 2025; .

PMID: 40069530 DOI: 10.1007/s13346-025-01829-5.


Optimizing Intranasal Amisulpride Loaded Nanostructured Lipid Carriers: Formulation, Development, and Characterization Parameters.

Tamer M, Kassab H Pharm Nanotechnol. 2025; 13(2):287-302.

PMID: 40007188 DOI: 10.2174/0122117385301604240226111533.


Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.

Amparo T, Almeida T, Sousa L, Xavier V, Silva G, Brandao G Pharmaceutics. 2025; 17(2).

PMID: 40006574 PMC: 11859672. DOI: 10.3390/pharmaceutics17020205.


Chitosan capped-NLCs enhanced codelivery of gefitinib and simvastatin into MDR HCC: impact of compositions on cell death, JNK3, and Telomerase.

Harisa G, Alzhrani R, Alluhaidan A, Alamri S, Bakheit A, Asiri H Oncol Res. 2025; 33(2):477-492.

PMID: 39866231 PMC: 11754001. DOI: 10.32604/or.2024.053337.


References
1.
Riley M, Vermerris W . Recent Advances in Nanomaterials for Gene Delivery-A Review. Nanomaterials (Basel). 2017; 7(5). PMC: 5449975. DOI: 10.3390/nano7050094. View

2.
Salem L, El-Feky G, Fahmy R, El Gazayerly O, Abdelbary A . Coated Lipidic Nanoparticles as a New Strategy for Enhancing Nose-to-Brain Delivery of a Hydrophilic Drug Molecule. J Pharm Sci. 2020; 109(7):2237-2251. DOI: 10.1016/j.xphs.2020.04.007. View

3.
Silva S, Bicker J, Fonseca C, Ferreira N, Vitorino C, Alves G . Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: Evaluation. Front Pharmacol. 2021; 12:751321. PMC: 8675330. DOI: 10.3389/fphar.2021.751321. View

4.
Duong V, Nguyen T, Maeng H, Chi S . Data on optimization and drug release kinetics of nanostructured lipid carriers containing ondansetron hydrochloride prepared by cold high-pressure homogenization method. Data Brief. 2019; 26:104475. PMC: 6811934. DOI: 10.1016/j.dib.2019.104475. View

5.
Haider M, Abdin S, Kamal L, Orive G . Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review. Pharmaceutics. 2020; 12(3). PMC: 7151211. DOI: 10.3390/pharmaceutics12030288. View